Gotowe bibliografie tematyczne / Glenzocimab

Spis treści

  1. Artykuły w czasopismach
  2. Rozprawy doktorskie
  3. Streszczenia konferencji

Gotowa bibliografia na temat „Glenzocimab”

Autor: Grafiati
Data publikacji: 9 listopada 2024
Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Glenzocimab”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Glenzocimab"

1

Pottecher, Julien, Francois Raffi, Martine Jandrot-Perrus, et al. "Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial." PLOS ONE 19, no. 6 (2024): e0302897. http://dx.doi.org/10.1371/journal.pone.0302897.

Pełny tekst źródła
Streszczenie:
Background Glenzocimab is a novel antithrombotic agent which targets platelet glycoprotein VI (GPVI) and does not induce haemorrhage. SARS-CoV-2 triggers a prothrombotic state and lung injury whose mechanisms include coagulopathy, endothelial dysfunction, and inflammation with dysregulated platelets. Methods and patients GARDEN was a randomised double-blind, exploratory phase II study of glenzocimab in SARS-CoV-2 respiratory failure (NCT04659109). PCR+ adults in Brazil and France (7 centres) were randomized to standard-of-care (SOC) plus glenzocimab (1000 mg/dayx3 days) or placebo, followed fo
Style APA, Harvard, Vancouver, ISO itp.
2

Renaud, Lionel, Kristell Lebozec, Christine Voors‐Pette, et al. "Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation." Journal of Clinical Pharmacology 60, no. 9 (2020): 1198–208. http://dx.doi.org/10.1002/jcph.1616.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Jandrot-Perrus, M., J. Pottecher, E. Toledano, et al. "PB0364 Glycoprotein VI-Targeted Antiplatelet Therapy with Glenzocimab is Safe in Patients Exposed to Current Antithrombotic and Fibrinolytic Drugs." Research and Practice in Thrombosis and Haemostasis 7 (October 2023): 101499. http://dx.doi.org/10.1016/j.rpth.2023.101499.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Comenducci, Andrea, Adeline Meilhoc, Yannick Pletan, et al. "Abstract 28: Patients Randomised to Glenzocimab Suffered Less Haemorrhagic Transformation at 24 Hours Compared to Placebo: AI-Imaging Sub-Analysis of the ACTIMIS Trial." Stroke 55, Suppl_1 (2024). http://dx.doi.org/10.1161/str.55.suppl_1.28.

Pełny tekst źródła
Streszczenie:
Introduction: ACTIMIS (NCT03803007) was a randomized phase 1b/2a clinical trial evaluating glenzocimab, a monoclonal antibody fragment targeting platelet receptor glycoprotein VI in patients with acute ischemic stroke treated by thrombolysis. Primary analysis demonstrated a reduction in intracranial hemorrhage occurrence stroke-related mortality. In this sub-analysis, volumetric imaging biomarkers were used to assess efficacy of glenzocimab. Methods: In the phase 2a study, patients were randomized (1:1) with 1000mg glenzocimab or placebo. CT or MRI was acquired at baseline with CT at 24 hours
Style APA, Harvard, Vancouver, ISO itp.
5

Comenducci, Andrea, Adeline Meilhoc, Yannick Pletan, et al. "Abstract 006: Glenzocimab Is Associated With Less Haemorrhagic Transformation Using Artificial Intelligence Imaging In Mechanical Thrombectomy Patients." Stroke: Vascular and Interventional Neurology 3, S2 (2023). http://dx.doi.org/10.1161/svin.03.suppl_2.006.

Pełny tekst źródła
Streszczenie:
Introduction Lesion volume measurement provides an objective and quantitative assessment of stroke severity and it is often used as a surrogate endpoint of clinical outcome in therapeutic trials. ACTIMIS (NCT03803007) was a randomized phase 1b/2a clinical trial evaluating glenzocimab, a monoclonal antibody fragment targeting platelet receptor glycoprotein VI, versus placebo in patients with acute ischemic stroke treated by thrombolysis alone or associated with mechanical thrombectomy (MT), both subgroups being well balanced. Primary analysis demonstrated a significant reduction in intracranial
Style APA, Harvard, Vancouver, ISO itp.
6

Wichaiyo, Surasak, Warisara Parichatikanond, and Wipharak Rattanavipanon. "Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke." Stroke, September 21, 2022. http://dx.doi.org/10.1161/strokeaha.122.039790.

Pełny tekst źródła
Streszczenie:
It has previously been shown in several animal experiments that platelet GPVI (glycoprotein VI) contributes to thrombosis, particularly in ischemic stroke. Moreover, GPVI levels are upregulated in stroke patients. This review describes the therapeutic roles of anti-GPVI antibody in preclinical models of ischemic stroke and provides the current evidence for potential benefits of glenzocimab, a Fab fragment of humanized anti-GPVI monoclonal antibody, in stroke patients. Anti-GPVI antibody, JAQ1, significantly decreased infarct volume and improved neurological function in mice with transient midd
Style APA, Harvard, Vancouver, ISO itp.
7

Alenazy, F. O., M. H. Harbi, D. P. Kavanagh, et al. "GPVI inhibition by glenzocimab synergistically inhibits atherosclerotic plaque-induced platelet activation when combined with conventional dual antiplatelet therapy." European Heart Journal 42, Supplement_1 (2021). http://dx.doi.org/10.1093/eurheartj/ehab724.1425.

Pełny tekst źródła
Streszczenie:
Abstract Introduction Aspirin and a potent platelet P2Y12 inhibitor, such as prasugrel or ticagrelor, are not always sufficient to prevent thrombus formation in patients with ST-elevation MI (STEMI), leading to “slow flow” or “no reflow” effects after stenting. GPIIb/IIIa inhibitors, such as eptifibatide, may help in this setting, but are not used routinely due to their bleeding risk. GPVI has critical roles in thrombosis and a minimal role in haemostasis. Here we tested whether depletion of GPVI has effects on thrombus formation after MI in an animal model and investigated the effects of a no
Style APA, Harvard, Vancouver, ISO itp.
8

Billiald, Philippe, Alexandre Slater, Martin Welin, et al. "Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition." Blood Advances, November 14, 2022. http://dx.doi.org/10.1182/bloodadvances.2022007863.

Pełny tekst źródła
Streszczenie:
Platelet glycoprotein VI (GPVI) is attracting interest as a potential target for the development of new antiplatelet molecules with a low bleeding risk. GPVI binding to vascular collagen initiates thrombus formation and GPVI interactions with fibrin promote the growth and stability of the thrombus. In the present study we show that glenzocimab, a clinical stage humanized antibody fragment (Fab) with high affinity for GPVI, blocks binding of both ligands through a combination of steric hindrance and structural change. A co-crystal of glenzocimab with an extracellular domain of monomeric GPVI wa
Style APA, Harvard, Vancouver, ISO itp.
9

Dupont, Sébastien, Héloïse Lebas, Sabrina Mavouna, et al. "Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage." Journal of the American Heart Association, January 17, 2025. https://doi.org/10.1161/jaha.123.034207.

Pełny tekst źródła
Streszczenie:
Background Antiplatelet drugs represent potential candidates for protecting the penumbral microcirculation during cerebral ischemia and improving the benefits of arterial recanalization in ischemic stroke. Yet while the efficacy of such adjuvant strategies has been shown to be highly time dependent, antiplatelet therapy at the acute phase of ischemic stroke cannot be envisioned until the diagnosis of stroke and its ischemic nature have been confirmed because of the presumed risk of worsening bleeding in case of intracranial hemorrhage (ICH). Here, we investigated this risk for 2 antiplatelet d
Style APA, Harvard, Vancouver, ISO itp.
10

Jadoui, Soumaya, Ophélie Le Chapelain, Véronique Ollivier, et al. "Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis." Haematologica, December 30, 2020. http://dx.doi.org/10.3324/haematol.2020.270439.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Glenzocimab"

1

Kern, Axelle Y. "La thrombose de stent : évaluation de l’importance de la rhéologie dans la thrombogénicité des stents et d’un nouvel agent pharmacologique dirigé contre la GPVI pour prévenir la thrombose de stent." Electronic Thesis or Diss., Strasbourg, 2024. http://www.theses.fr/2024STRAJ027.

Pełny tekst źródła
Streszczenie:
Une complication majeure de la pose d’un stent sur une plaque d’athérosclérose est la thrombose de stent, qui présente un taux de mortalité particulièrement élevé. La bithérapie antiplaquettaire, indiquée dans la prévention de cette complication, entraîne un risque important de saignement et n’est pas toujours efficace. L’objectif de ce travail de thèse a consisté à identifier les mécanismes de la thrombose de stent et à évaluer l’intérêt d’une nouvelle classe d'agents antiplaquettaires capables de la prévenir efficacement avec un risque hémorragique faible. Le développement d’un modèle macrof
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Glenzocimab"

1

Pottecher, J., V. A. H. Sato, Y. Plétan, et al. "A Novel Anti-Thrombotic, Glenzocimab, in Covid-19 acute respiratory distress syndrome (Cov-ARDS)." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.2878.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Köhrmann, Martin, Elie Toledano, Yannick Plétan, et al. "P024 ACTISAVE study: efficacy and safety of glenzocimab on top of thrombolysis and mechanical thrombectomy." In 16th Congress of the European Society of Minimally Invasive Neurological Therapy (ESMINT) 2024. BMJ Publishing Group Ltd., 2024. http://dx.doi.org/10.1136/jnis-2024-esmint.61.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Glenzocimab” dla poszczególnych typów źródeł:
Artykuły w czasopismach
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii